Influvac Tetra (quadrivalent influenza vaccine) / Viatris - LARVOL DELTA

Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine As a Booster on Participants Previously Administered with OVX836 (clinicaltrials.gov) - P2 | N=160 | Active, not recruiting | Sponsor: Osivax | Not yet recruiting ➔ Active, not recruiting | Trial primary completion date: Mar 2025 ➔ Jun 2025

Enrollment closed • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

Immunogenicity and Safety of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836 (clinicaltrials.gov) - P2 | N=214 | Not yet recruiting | Sponsor: Osivax

New P2 trial • Infectious Disease • Influenza • Respiratory Diseases • IFNG

Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Parc Taulí Hospital Universitari

New trial • CNS Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Sleep Apnea • Sleep Disorder • IFNG • IL10 • IL1B • IL6

Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2023-2024. (PubMed, Can Commun Dis Rep) - "Key changes for the 2023-2024 season include: 1) incorporation of updated information/guidance on influenza vaccination in the context of the coronavirus disease 2019 (COVID-19); 2) new recommendations for Flucelvax® Quad and Influvac® Tetra, the two quadrivalent inactivated influenza vaccines with expanded paediatric age indications; and 3) an update to the format of the Statement. Overall, NACI continues to recommend that an age-appropriate influenza vaccine should be offered annually to all individuals aged six months and older who do not have a contraindication to the vaccine, with particular focus on the groups for whom influenza vaccination is particularly recommended."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases

Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity. (PubMed, Expert Rev Vaccines) - "ECDC recommends that EU Member States implement action plans and policies aimed at reaching 75% coverage in at-risk groups and healthcare workers. Even so, vaccine coverage is still far from recommended."

Journal • Review • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Immune Responses after One Versus Two Influenza A/B Vaccinations in Patients with Multiple Myeloma (ASH 2023) - "Data from the pre-lenalidomide era highlighted poor vaccination responses, with sufficient seroconversion in 39% of patients with MM after single vaccination and an increase to 55% after additional boosting... In this retrospective single-center study, we analyzed the serological response from 71 patients with MM treated at our institution who received the annual Influenza A/B vaccination (Influvac Tetra, Mylan, Troisdorf, Germany) in the 2019/20 season... Together, 63.3% of patients with MM achieved a sufficient serological response after tetravalent Influenza A/B vaccination without a significant general benefit for a prime and boost approach. Current therapy, uncontrolled MM, present immunoparesis and low CD19+ B-cell counts were associated with inferior response rates. Those patients exceptionally benefitting from a boost vaccination were characterized by recent autoHSCT."

Clinical • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Influenza • Multiple Myeloma • Oncology • Respiratory Diseases • Transplantation • CD4

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines. (PubMed, JAMA Netw Open) - "This prospective cohort study included health care workers at a large tertiary medical center in Israel who received the Influvac Tetra (Abbott) influenza vaccine (2022/2023), the Omicron BA.4/BA.5-adapted bivalent (Pfizer/BioNTech) vaccine, or both. Geometric mean titers in the coadministration group were estimated to be 0.84 (95% CI, 0.69-1.04) times lower than in the COVID-19 vaccine-alone group. In this cohort study of health care workers who received a COVID-19 vaccine, an influenza vaccine, or both, coadministration was not associated with substantially inferior immune response or to more frequent adverse events compared with COVID-19 vaccine administration alone, supporting the coadministration of these vaccines."

Journal • Fatigue • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Results from the Enhanced Passive Safety Surveillance for the influenza vaccine Influvac® Tetra in Germany and Italy during 2022/2023 vaccination season (ESWI 2023) - No abstract available

Clinical • Infectious Disease • Influenza • Respiratory Diseases

Phase I clinical study to evaluate the safety and tolerability of Quadrivalent Influenza Vaccine (QIV) delivered intradermally by a high-density micro-array patch (HD MAP), compared to intramuscular Influvac® Tetra injection, in healthy adults aged 18 to 50 years (ANZCTR) - P=N/A | N=150 | Recruiting | Sponsor: Vaxxas Pty Ltd | Initiation date: Nov 2000 ➔ Nov 2022

Trial initiation date • Infectious Disease • Influenza • Respiratory Diseases

Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. (PubMed, J Infect Public Health) - "Recent influenza vaccination is associated with a significant reduction in the risk of SARS-CoV-2 infection and COVID-19 severity."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Enhanced passive safety surveillance of Influvac® and Influvac® Tetra: Results from seven consecutive seasons. (PubMed, Vaccine) - "The EPSS set up for Influvac® and Influvac® Tetra proved a robust and effective methodology to comply with the objectives of EMÁ's guidance on enhanced safety surveillance of seasonal influenza vaccines. Safety data from seven consecutive seasons confirmed the favourable safety profile of both vaccines."

Journal • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases